|
1
|
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman
M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C,
et al: Heart disease and stroke statistics-2017 update: A report
from the American heart association. Circulation. 135:e146–e603.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Normand C, Kaye DM, Povsic TJ and
Dickstein K: Beyond pharmacological treatment: An insight into
therapies that target specific aspects of heart failure
pathophysiology. Lancet. 393:1045–1055. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hunt SA, Baker DW, Chin MH, Cinquegrani
MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G,
Jessup ML, et al: ACC/AHA guidelines for the evaluation and
management of chronic heart failure in the adult: Executive
summary. A report of the American college of cardiology/American
heart association task force on practice guidelines (committee to
revise the 1995 guidelines for the evaluation and management of
heart failure). J Am Coll Cardiol. 38:2101–2113. 2001.PubMed/NCBI View Article : Google Scholar
|
|
4
|
O'Connor CM: HFpEF: From early
observations to worldwide awareness. JACC. Heart Fail. 6:718–719.
2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ponikowski P, Voors AA, Anker SD, Bueno H,
Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP,
Jankowska EA, et al: 2016 ESC guidelines for the diagnosis and
treatment of acute and chronic heart failure: The task force for
the diagnosis and treatment of acute and chronic heart failure of
the european society of cardiology (ESC). Developed with the
special contribution of the heart failure association (HFA) of the
ESC. Eur J Heart Fail. 18:891–975. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Verma S, McGuire DK and Kosiborod MN: Two
tales: One story: EMPEROR-reduced and DAPA-HF. Circulation.
142:2201–2204. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Aimo A, Pateras K, Stamatelopoulos K,
Bayes-Genis A, Lombardi CM, Passino C, Emdin M and Georgiopoulos G:
Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2
inhibitors in heart failure with reduced ejection fraction: A
systematic review and network meta-analysis. Cardiovasc Drugs Ther.
35:1067–1076. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Song M, Mihara K, Chen Y, Scorrano L and
Dorn GW II: Mitochondrial fission and fusion factors reciprocally
orchestrate mitophagic culling in mouse hearts and cultured
fibroblasts. Cell Metab. 21:273–286. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Twig G, Elorza A, Molina AJ, Mohamed H,
Wikstrom JD, Walzer G, Stiles L, Haigh SE, Katz S, Las G, et al:
Fission and selective fusion govern mitochondrial segregation and
elimination by autophagy. EMBO J. 27:433–446. 2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tham YK, Bernardo BC, Ooi JY, Weeks KL and
McMullen JR: Pathophysiology of cardiac hypertrophy and heart
failure: Signaling pathways and novel therapeutic targets. Arch
Toxicol. 89:1401–1438. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Brown DA, Perry JB, Allen ME, Sabbah HN,
Stauffer BL, Shaikh SR, Cleland JG, Colucci WS, Butler J, Voors AA,
et al: Expert consensus document: Mitochondrial function as a
therapeutic target in heart failure. Nat Rev Cardiol. 14:238–250.
2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Fan ZG, Xu Y, Chen X, Ji MY and Ma GS:
Appropriate dose of dapagliflozin improves cardiac outcomes by
normalizing mitochondrial fission and reducing cardiomyocyte
apoptosis after acute myocardial infarction. Drug Des Devel Ther.
16:2017–2030. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Writing Committee Members. Lawton JS,
Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM,
Bittl JA, Cohen MG, DiMaio JM, et al: 2021 ACC/AHA/SCAI guideline
for coronary artery revascularization: A report of the American
college of cardiology/American heart association joint committee on
clinical practice guidelines. J Am Coll Cardiol. 79:e21–e129.
2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Heidenreich PA, Bozkurt B, Aguilar D,
Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM,
Evers LR, et al: 2022 AHA/ACC/HFSA guideline for the management of
heart failure: A report of the American college of
cardiology/American heart association joint committee on clinical
practice guidelines. Circulation. 145:e895–e1032. 2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Stone GW, Lindenfeld J, Abraham WT, Kar S,
Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia
SR, et al: Transcatheter mitral-valve repair in patients with heart
failure. N Engl J Med. 379:2307–2318. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yancy CW, Jessup M, Bozkurt B, Butler J,
Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi
JL, et al: 2013 ACCF/AHA guideline for the management of heart
failure: A report of the American college of cardiology
foundation/American heart association task force on practice
guidelines. J Am Coll Cardiol. 62:e147–e239. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wilcox JE, Fonarow GC, Ardehali H, Bonow
RO, Butler J, Sauer AJ, Epstein SE, Khan SS, Kim RJ, Sabbah HN, et
al: ‘Targeting the heart’ in heart failure: Myocardial recovery in
heart failure with reduced ejection fraction. JACC Heart Fail.
3:661–669. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hernandez AF, Hammill BG, O'Connor CM,
Schulman KA, Curtis LH and Fonarow GC: Clinical effectiveness of
beta-blockers in heart failure: Findings from the OPTIMIZE-HF
(organized program to initiate lifesaving treatment in hospitalized
patients with heart failure) registry. J Am Coll Cardiol.
53:184–192. 2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Pitt B, Pfeffer MA, Assmann SF, Boineau R,
Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, et al:
Spironolactone for heart failure with preserved ejection fraction.
N Engl J Med. 370:1383–1392. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Massie BM, Carson PE, McMurray JJ, Komajda
M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger
C, et al: Irbesartan in patients with heart failure and preserved
ejection fraction. N Engl J Med. 359:2456–2467. 2008.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Bhagat AA, Greene SJ, Vaduganathan M,
Fonarow GC and Butler J: Initiation, continuation, switching, and
withdrawal of heart failure medical therapies during
hospitalization. JACC Heart Fail. 7:1–12. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
McMurray JJV, Solomon SD, Inzucchi SE,
Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS,
Anand IS, Bělohlávek J, et al: Dapagliflozin in patients with heart
failure and reduced ejection fraction. N Engl J Med. 381:1995–2008.
2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Anker SD, Butler J, Filippatos G, Ferreira
JP, Bocchi E, Böhm M, Brunner–La Rocca HP, Choi DJ, Chopra V,
Chuquiure-Valenzuela E, et al: Empagliflozin in heart failure with
a preserved ejection fraction. N Engl J Med. 385:1451–1461.
2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhuang L, Jia K, Chen C, et al:
DYRK1B-STAT3 Drives Cardiac Hypertrophy and Heart Failure by
Impairing Mitochondrial Bioenergetics. Circulation. Mar 15
2022;145(11):829-846.
|
|
25
|
Imoto M, Tachibana I and Urrutia R:
Identification and functional characterization of a novel human
protein highly related to the yeast dynamin-like GTPase Vps1p.
Journal of cell science. May 1998;111 (Pt 10):1341-1349.
|
|
26
|
Yoon Y, Pitts KR, Dahan S and McNiven MA:
A novel dynamin-like protein associates with cytoplasmic vesicles
and tubules of the endoplasmic reticulum in mammalian cells. J Cell
Biol. 140:779–793. 1998.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Tong M, Zablocki D and Sadoshima J: The
role of Drp1 in mitophagy and cell death in the heart. J Mol Cell
Cardiol. 142:138–145. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ferrannini E, Mark M and Mayoux E: CV
protection in the EMPA-REG OUTCOME trial: A ‘thrifty substrate’
hypothesis. Diabetes Care. 39:1108–1114. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Jose Corbalan J, Vatner DE and Vatner SF:
Myocardial apoptosis in heart disease: does the emperor have
clothes? Basic Res Cardiol. 111(31)2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lam CS, Donal E, Kraigher-Krainer E and
Vasan RS: Epidemiology and clinical course of heart failure with
preserved ejection fraction. Eur J Heart Fail. 13:18–28.
2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Chen X, Liang J, Bin W, Luo H and Yang X:
Anti-hyperlipidemic, anti-inflammatory, and ameliorative effects of
DRP1 inhibition in rats with experimentally induced myocardial
infarction. Cardiovasc Toxicol. 21:1000–1011. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Virmani R, Kolodgie FD, Burke AP, Farb A
and Schwartz SM: Lessons from sudden coronary death: A
comprehensive morphological classification scheme for
atherosclerotic lesions. Arterioscler Thromb Vasc Biol.
20:1262–1275. 2000.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kumar A, Avishay DM, Jones CR, Shaikh JD,
Kaur R, Aljadah M, Kichloo A, Shiwalkar N and Keshavamurthy S:
Sudden cardiac death: epidemiology, pathogenesis and management.
Rev Cardiovasc Med. 22:147–158. 2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Shirakabe A, Zhai P, Ikeda Y, Saito T,
Maejima Y, Hsu CP, Nomura M, Egashira K, Levine B and Sadoshima J:
Drp1-dependent mitochondrial autophagy plays a protective role
against pressure overload-induced mitochondrial dysfunction and
heart failure. Circulation. 133:1249–1263. 2016.PubMed/NCBI View Article : Google Scholar
|
